These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24706489)

  • 1. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
    Giagounidis A; Mufti GJ; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Hu K; Woodard P; Yang AS; Kantarjian HM
    Cancer; 2014 Jun; 120(12):1838-46. PubMed ID: 24706489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
    Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
    Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
    Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
    J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
    Greenberg PL; Garcia-Manero G; Moore M; Damon L; Roboz G; Hu K; Yang AS; Franklin J
    Leuk Lymphoma; 2013 Feb; 54(2):321-8. PubMed ID: 22906162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
    Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
    Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
    Kantarjian HM; Giles FJ; Greenberg PL; Paquette RL; Wang ES; Gabrilove JL; Garcia-Manero G; Hu K; Franklin JL; Berger DP
    Blood; 2010 Oct; 116(17):3163-70. PubMed ID: 20631375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.
    Wang ES; Lyons RM; Larson RA; Gandhi S; Liu D; Matei C; Scott B; Hu K; Yang AS
    J Hematol Oncol; 2012 Nov; 5():71. PubMed ID: 23190430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
    Sekeres MA; Giagounidis A; Kantarjian H; Mufti GJ; Fenaux P; Jia C; Yang AS; Platzbecker U
    Br J Haematol; 2014 Nov; 167(3):337-45. PubMed ID: 25039607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP).
    Gernsheimer TB; George JN; Aledort LM; Tarantino MD; Sunkara U; Matthew Guo D; Nichol JL
    J Thromb Haemost; 2010 Jun; 8(6):1372-82. PubMed ID: 20230419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
    Prica A; Sholzberg M; Buckstein R
    Br J Haematol; 2014 Dec; 167(5):626-38. PubMed ID: 25155450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia.
    Weitz I; Sanz MA; Henry D; Schipperus M; Godeau B; Northridge K; Gleeson M; Danese M; Deuson R
    Curr Med Res Opin; 2012 May; 28(5):789-96. PubMed ID: 22494019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
    Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Okamoto S; Kurokawa M; Kirito K; Yonemura Y; Mori S; Usuki K; Iwato K; Hashino S; Wei H; Lizambri R
    Int J Hematol; 2011 Jul; 94(1):71-80. PubMed ID: 21706145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.
    Platzbecker U; Sekeres MA; Kantarjian H; Giagounidis A; Mufti GJ; Jia C; Yang AS; Fenaux P
    Leukemia; 2014 Dec; 28(12):2418-21. PubMed ID: 25179731
    [No Abstract]   [Full Text] [Related]  

  • 18. Romiplostim for the management of perioperative thrombocytopenia.
    Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
    Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
    Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
    Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
    Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.